Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report.

Ohnari, Kana; Hashimoto, Tomoyo; Iwanaka, Yukio; Ohnari, Keiko; Adachi, Hiroaki; Okada, Kazumasa

Ohnari, Kana; Hashimoto, Tomoyo; Iwanaka, Yukio; Ohnari, Keiko; Adachi, Hiroaki; Okada, Kazumasa.

Afiliação

Ohnari K; Department of Neurology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Hashimoto T; Department of Neurology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. h-tomoyo@med.uoeh-u.ac.jp.
Iwanaka Y; Department of Neurology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Ohnari K; Department of Neurology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Adachi H; Department of Neurology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Okada K; Department of Neurology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

J Neurol ; 271(5): 2902-2905, 2024 May.

Article em En | MEDLINE | ID: mdl-38393426

Assuntos

Anticorpos Monoclonais Humanizados; Miastenia Gravis; Humanos; Anticorpos Monoclonais Humanizados/uso terapêutico; Anticorpos Monoclonais Humanizados/farmacologia; Inativadores do Complemento/uso terapêutico; Inativadores do Complemento/farmacologia; Miastenia Gravis/tratamento farmacológico; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Miastenia Gravis Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google